Tuberculosis (TB) is the main cause of death by infectiousdisease worldwide. Immunocompromised cancer patients are at riskfor tuberculosis infection as they are immunosupressed, thereforescreening for latent tuberculous infection, using the tuberculin skintest and QuantiFERON-TB Gold test remain an integral part oftuberculosis control program for immunocompromised group.The present study compared the performance of tuberculin skintest with that of QuantiFERON-TB Gold test in detecting latenttuberculous infection in 40 cancer patients admitted in NaserInstitute Hospital. All patients underwent tuberculin skin test andQuantiFERON-TB Gold test.In the current study, 15 out of 40 cancer patients (37.5%) werefound to be positive by tuberculin skin test and two patients (5%)were positive by QuantinFERON- TB Gold test, 9 patients gaveindeterminate QuantiFERON-TB Gold test results and 29 patientswere QuantiFERON-TB Gold test negative amongimmunocompromised cancer patients.Agreement between the TST and QuantiFERON-TB Gold testwas 19/31 (61%) after exclusion of the indeterminateQuantiFERON-TB Gold test results. However we did not reachstatistical significance by kappa (k = 0.155 ; p = 0.107), so weconcluded that the two tests may be complementary to each other indiagnosis of latent tuberculous infection.